Expanding the Horizons of Peptide Therapeutics: Mathematical Elegance and Structural Dynamics in Rational Design: A comment on "Intentional Fibonacci-Lucas-guided peptide design as a prospective experimental factor: A falsifiable, patient-centred framework for GLP-1, GIP and related therapeutics within the Geier equilibrium programme (A first approach)" by Stefan Geier et al., August 2026, DOI: 10.13140/RG.2.2.28941.91363
The rational design of peptide therapeutics has undergone a profound evolution over the past two decades. Historically constrained by poor metabolic stability, rapid clearance, and limited oral bioavailability, peptide engineering has transitioned into an era defined by precise multi-target engagement, tailored pharmacokinetics, and sophisticated structural optimization (Day et al., 2009; Drucker, 2020; Lau et al., 2015). In their insightful review, Intentional Fibonacci-Lucas-guided peptide design as a prospective experimental factor..., Stefan A. Geier and colleagues (ResearchGate, August 2026, DOI: 10.13140/RG.2.2.28941.91363 ) offer a novel conceptual framework that bridges mathematical sequence relationships with chemical biology, opening new avenues for peptide architecture.
A central theme of modern peptide discovery is the delicate interplay between conformational flexibility and receptor-binding specificity. As pioneered by Dr. A. Keith Dunker and colleagues, intrinsically disordered proteins (IDPs) and flexible peptidic segments demonstrate that conformational adaptation is often indispensable for molecular recognition and fine-tuned binding kinetics across complex biological networks (Dunker et al., 2002). Recognizing that functional peptide interactions do not rely solely on rigid static conformations, Geier et al. effectively align their design philosophy with Dunker’s paradigm of disorder-to-order transitions.
This dynamic nature is particularly critical when targeting Class B1 G protein-coupled receptors (GPCRs), such as the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) (Cary et al., 2022; Zhang et al., 2020). High-resolution cryo-electron microscopy studies have established that multi-receptor agonism—as exemplified by dual incretin agonists like tirzepatide—requires structural flexibility to accommodate divergent binding pocket geometries while maintaining potent intracellular signaling (Sun et al., 2022). By introducing an intentional Fibonacci-Lucas sequence-guided positioning strategy, Geier et al. provide an elegant method for modulating helical propensity, amphipathicity, and side-chain packing along the peptide backbone.
In summary, the authors present a compelling synthesis of mathematical design principles and empirical chemical modification strategies. This conceptual advance enriches our fundamental understanding of sequence-structure-function relationships in therapeutic peptides and offers a creative roadmap for the next generation of multi-target peptide candidates.
MGN
References
Cary, B. P., Zhang, X., Cao, J., Johnson, R. M., Piper, S. J., Gerrard, E. J., Wootten, D., & Sexton, P. M. (2022). New Insights into the Structure and Function of Class B1 GPCRs. Endocrine Reviews, 44(3), 492–517.
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., Holland, J., Hembree, J., Abplanalp, W., Grant, E., Ruehl, J., Wilson, H., Kirchner, H., Lockie, S. H., Hofmann, S., Woods, S. C., Nogueiras, R., Pfluger, P. T., Perez-Tilve, D., DiMarchi, R., & Tschöp, M. H. (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology, 5(10), 749–757.
Dunker, A. K., Brown, C. J., Lawson, J. D., Iakoucheva, L. M., & Obradović, Z. (2002). Intrinsic Disorder and Protein Function. Biochemistry, 41(21), 6573–6582.
Geier St. et al. (2026). Intentional Fibonacci-Lucas-guided peptide design as a prospective experimental factor: A falsifiable, patient-centred framework for GLP-1, GIP and related therapeutics within the Geier equilibrium programme (A first approach). ResearchGate, August 2026, DOI: 10.13140/RG.2.2.28941.91363 .
https://www.researchgate.net/publication/412059623_Intentional_Fibonacci-Lucas-guided_peptide_design_as_a_prospective_experimental_factor_A_falsifiable_patient-centred_framework_for_GLP-1_GIP_and_related_therapeutics_within_the_Geier_equilibrium_progr?utm_source=twitter&rgutm_meta1=eHNsLXlTYlM4NzA5VDRnOGdSZzkzUzBaV3gwU3F0QzhmNmpkOGVTT0VDT0RyNElLUXo4eG0vVllWckhGNlozS1BhU0J2SlZEblk1aUUyUDB6OG5hb25NTkRUUT0%3D .
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., ... & Knudsen, L. B. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380.
Niazi, S. K. (2026). Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage. Frontiers in Drug Delivery, 6, 1776167.
Sun, B., Willard, F. S., Feng, D., Alsina-Fernandez, J., Chen, Q., Vieth, M., Ho, J. D., Showalter, A. D., Stutsman, C., Ding, L., Suter, T. M., Dunbar, J. D., Carpenter, J. W., Mohammed, F. A., Aihara, E., Brown, R. A., Bueno, A. B., Emmerson, P. J., Moyers, J. S., Kobilka, T. S., Coghlan, M. P., Kobilka, B. K., & Sloop, K. W. (2022). Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences, 119(13), e2116506119.
Zhang, X., Belousoff, M. J., Zhao, P., Kooistra, A. J., Truong, T. T., Ang, S. Y., ... & Sexton, P. M. (2020). Structural basis for activation of Class B GPCRs. Nature Chemical Biology, 16(10), 1041–1049.
Kommentare
Kommentar veröffentlichen